Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

JNGLX Janus Henderson Global Life Sciences D

  • Fund
  • JNGLX
  • Price as of: Jul 19, 2019
  • $57.91 - $0.49 - 0.84%
  • Category
  • Health & Biotech Equities

JNGLX - Profile

Vitals

  • YTD Return 14.8%
  • 3 Yr Annualized Return 4.8%
  • 5 Yr Annualized Return 3.8%
  • Net Assets $3.96 B
  • Holdings in Top 10 30.0%

52 WEEK LOW AND HIGH

$57.91
$47.36
$65.84

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.82%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 46.00%

TRADING FEES

  • Max Redemption Fee 2.00%

Min Investment

Closed to new investors as of Feb 12, 2010

STANDARD (TAXABLE)

$2,500

IRA

$1,000

Investment Themes

CATEGORY

Health & Biotech Equities
  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 15.7%
  • 3 Yr Annualized Total Return 5.7%
  • 5 Yr Annualized Total Return 8.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.20%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Semi-Annually

Fund Details

  • Legal Name Janus Henderson Global Life Sciences Fund
  • Fund Family Name Janus Henderson
  • Inception Date Dec 31, 1998
  • Shares Outstanding N/A
  • Share Class D
  • Currency USD
  • Domiciled Country United States
  • Manager Andrew Acker

Fund Description

The Janus Global Life Sciences Fund Class D (JNGLX) is a low-cost, actively managed fund focused on the health care sector. The fund holds a wide range of health care-related equities from around the world and can invest in any market-cap size. JNGLX balances its investments in the biotech, traditional pharmaceuticals and health care equipment/services sphere in order to help reduce volatility.

As a specialized health care fund, JNGLX should only be used as a satellite position in a broader equity portfolio. The fund is managed by Janus Capital Management.

JNGLX - Performance

Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 14.8% 1.8% 36.6% 28.43%
1 Yr -7.1% -25.3% 9.3% 62.75%
3 Yr 4.8%* -17.5% 21.7% 36.27%
5 Yr 3.8%* -11.3% 17.8% 34.69%
10 Yr N/A* -1.8% 15.6% N/A

* Annualized


Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.9% -25.3% 7.7% 53.92%
2017 21.1% -10.8% 43.9% 37.25%
2016 -13.4% -29.8% 2.6% 42.16%
2015 -0.8% -20.4% 13.8% 31.37%
2014 22.3% -5.8% 31.5% 21.43%

Total Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 15.7% 1.8% 36.6% 29.41%
1 Yr -6.3% -25.3% 12.9% 66.67%
3 Yr 5.7%* -17.5% 24.8% 52.94%
5 Yr 8.3%* -11.3% 19.8% 31.63%
10 Yr N/A* -1.8% 18.8% N/A

* Annualized


Total Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.9% -25.3% 12.3% 61.76%
2017 22.6% -10.8% 45.8% 33.33%
2016 -13.1% -24.2% 8.7% 57.84%
2015 8.2% -16.6% 15.2% 27.45%
2014 35.4% -5.8% 36.7% 2.04%

NAV & Total Return History

JNGLX - Holdings

Concentration Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Assets 3.96 B 13.8 M 44.7 B 26.47%
Number of Holdings 89 30 392 43.14%
Net Assets in Top 10 1.19 B 6.7 M 18.8 B 30.39%
Weighting of Top 10 29.97% 25.1% 75.2% 94.12%

Top 10 Holdings

  1. Merck & Co Inc 4.39%

  2. Novartis AG ADR 3.52%

  3. Takeda Pharmaceutical Co Ltd 3.22%

  4. Abbott Laboratories 3.04%

  5. AstraZeneca PLC 2.79%

  6. UnitedHealth Group Inc 2.70%

  7. Thermo Fisher Scientific Inc 2.69%

  8. Anthem Inc 2.68%

  9. AbbVie Inc 2.59%

  10. Humana Inc 2.35%


Asset Allocation

Weighting Return Low Return High JNGLX % Rank
Stocks
97.20% 91.85% 103.82% 59.80%
Other
1.72% -3.83% 2.75% 10.78%
Cash
1.08% 0.00% 5.40% 71.57%
Preferred Stocks
0.00% 0.00% 2.32% 24.51%
Convertible Bonds
0.00% 0.00% 0.12% 11.76%
Bonds
0.00% 0.00% 0.66% 17.65%

Stock Sector Breakdown

Weighting Return Low Return High JNGLX % Rank
Healthcare
95.10% 10.92% 99.42% 52.94%
Technology
1.42% 0.00% 62.64% 46.08%
Utilities
0.00% 0.00% 0.00% 10.78%
Real Estate
0.00% 0.00% 1.35% 19.61%
Industrials
0.00% 0.00% 12.61% 43.14%
Financial Services
0.00% 0.00% 5.80% 20.59%
Energy
0.00% 0.00% 0.09% 13.73%
Communication Services
0.00% 0.00% 0.00% 10.78%
Consumer Defense
0.00% 0.00% 0.69% 20.59%
Consumer Cyclical
0.00% 0.00% 8.52% 35.29%
Basic Materials
0.00% 0.00% 1.92% 47.06%

Stock Geographic Breakdown

Weighting Return Low Return High JNGLX % Rank
US
75.66% 60.46% 99.29% 77.45%
Non US
21.54% 0.00% 39.02% 24.51%

JNGLX - Expenses

Operational Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.82% 0.10% 2.98% 84.31%
Management Fee 0.64% 0.09% 1.25% 40.20%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.12% 0.01% 0.40% 55.93%

Sales Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee 2.00% 0.75% 2.00% 12.50%

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 46.00% 0.00% 341.00% 71.57%

JNGLX - Distributions

Dividend Yield Analysis

JNGLX Category Low Category High JNGLX % Rank
Dividend Yield 0.00% 0.00% 0.01% 29.41%

Dividend Distribution Analysis

JNGLX Category Low Category High Category Mode
Dividend Distribution Frequency Semi-Annually Annually Annually Annually

Dividend Payout History


Net Income Ratio Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Income Ratio 0.20% -2.15% 1.48% 18.63%

Capital Gain Distribution Analysis

JNGLX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

JNGLX - Managers

Andrew Acker

Manager

Start Date

Tenure

Tenure Rank

May 01, 2007

12.17

12.2%

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation.


Tenure Analysis

Category Low

0.08

Category High

21.8

Category Average

10.26

Category Mode

19.18